Syndax Pharmaceuticals (SNDX) Cash from Operations Growth (3y) (2018 - 2026)

Syndax Pharmaceuticals (SNDX) Cash from Operations Growth (3y) (2018 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -5.07%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 33.08%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 16.64%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -7.60%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Syndax Pharmaceuticals 1.83 Bn 1.48 Bn 53.02 Mn -8.67%

Historic Data

Download Data
DateValue
Mar 31, 2026 -8.67%
Dec 31, 2025 -44.79%
Sep 30, 2025 -35.20%
Jun 30, 2025 -29.63%
Mar 31, 2025 -31.41%
Dec 31, 2024 -36.97%
Sep 30, 2024 -35.69%
Jun 30, 2024 -43.90%
Mar 31, 2024 -54.65%
Dec 31, 2023 -38.30%
Sep 30, 2023 -34.63%
Jun 30, 2023 -18.22%
Mar 31, 2023 -35.05%
Dec 31, 2022 -21.62%
Sep 30, 2022 -49.58%
Jun 30, 2022 -47.64%
Mar 31, 2022 -35.56%
Dec 31, 2021 105.63%
Sep 30, 2021 -10.54%
Jun 30, 2021 -16.65%